Intellia Therapeutics lands non-dilutive OrbiMed debt facility up to $400M
Intellia Therapeutics secured a non-dilutive debt facility with OrbiMed for up to $400 million: $75 million funded upfront and $325 million tied to milestones, aimed at added strategic flexibility.
$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection pointsCAMBRIDGE, Mass., Sept.
04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
NASDAQ:NTLA, a leading biopharmaceutical company focused on revo…